Stay updated with breaking news from Expert View. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sudeep Shah, from SBI Securities, predicts market consolidation and bullish movement towards 22,950-23,000. He further Recommends Aditya Birla Capital and MCX stocks and anticipates positive trends in the pharma sector, specifically mentioning Concord Bio.
Market expert Joshi praises TCS's outstanding financial performance, expecting a stock re-rating. Anticipates positive sector impact and growth in BFSI, energy, manufacturing, life sciences, and healthcare industries based on TCS's stellar results.
Foram Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus's earnings improvement, Sun Pharma's specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy's.
S Krishnakumar shares insights on market performance, cautioning on high valuations and potential earnings surprises in auto ancillaries. He highlights megatrends in renewables, e-commerce, and manufacturing, stressing the need for strategic investment timing. Krishnakumar further says that "opportunities are very rare to come by where there is a lot more comfort in valuation. This is a market which is well priced in ."
Swarup Mohanty of Mirae Asset Global Investments advises rebalancing portfolios, predicting SIPs will reach Rs 25,000 per head per month by December 2024. Mohanty emphasizes the importance of investing in good companies and suggests a higher allocation to largecaps for portfolio stability. "if you have bought more of the smaller companies, it is time to rebalance," he says.